Convergent Therapeutics Announces Two Clinical Trial Updates on CONV01-α at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2025

Posted on by

– Phase I Follow-Up Data Showed an Overall Survival of 29.8 Months with the Addition of CONV01-α to 177Lu-PSMA-I&T in Advanced Prostate Cancer CAMBRIDGE, Mass., Feb. 10, 2025 /PRNewswire/ — Convergent Therapeutics Inc., a clinical-stage biotechnology company focused on the development of…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.